- Home
- CWK vs CELC Comparison
CWK vs CELC Comparison
Compare CWK & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWK | CELC |
|---|---|---|
| Founded | 1784 | 2011 |
| Country | United States | United States |
| Employees | 53000 | N/A |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CWK | CELC |
|---|---|---|
| Price | $14.33 | $121.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $17.64 | ★ $107.88 |
| AVG Volume (30 Days) | ★ 1.3M | 673.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $10,288,200,000.00 | N/A |
| Revenue This Year | $6.87 | N/A |
| Revenue Next Year | $5.98 | $720.19 |
| P/E Ratio | $37.55 | ★ N/A |
| Revenue Growth | ★ 8.91 | N/A |
| 52 Week Low | $8.67 | $9.64 |
| 52 Week High | $17.40 | $128.28 |
Technical Indicators
Market Signals| Indicator | CWK | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 53.06 |
| Support Level | $11.62 | $99.38 |
| Resistance Level | $16.41 | N/A |
| Average True Range (ATR) | 0.56 | 6.94 |
| MACD | 0.13 | -0.34 |
| Stochastic Oscillator | 66.73 | 63.25 |
Price Performance
Historical ComparisonAbout CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such as valuation, project management, and facilities management.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.